These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 30027641)

  • 1. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
    Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
    Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
    Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
    Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
    Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
    Suzuki K; Sunami K; Matsumoto M; Maki A; Shimada F; Suzuki K; Shimizu K
    Acta Haematol; 2021; 144(3):264-274. PubMed ID: 33279887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study.
    Terpos E; Gobbi M; Potamianou A; Lahaye M; Couturier C; Cavo M
    Eur J Haematol; 2018 Jan; 100(1):10-19. PubMed ID: 28801967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.
    Ahn JS; Jung SH; Lee SS; Ahn SY; Yang DH; Kim YK; Kim HJ; Lee JJ
    Biomed Res Int; 2014; 2014():145843. PubMed ID: 25530955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 10. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.
    White D; Kassim A; Bhaskar B; Yi J; Wamstad K; Paton VE
    Cancer; 2013 Jan; 119(2):339-47. PubMed ID: 22811009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
    Orlowski RZ; Moreau P; Niesvizky R; Ludwig H; Oriol A; Chng WJ; Goldschmidt H; Yang Z; Kimball AS; Dimopoulos M
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):522-530.e1. PubMed ID: 31160237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
    Goldschmidt H; Moreau P; Ludwig H; Niesvizky R; Chng WJ; Joshua D; Weisel K; Spencer A; Orlowski RZ; Feng S; Iskander KS; Dimopoulos MA
    Leuk Lymphoma; 2018 Jun; 59(6):1364-1374. PubMed ID: 28937327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma.
    Reece DE; Trieu Y; Masih-Khan E; Atenafu EG; Chen C; Prica A; Tiedemann R; Trudel S; Kukreti V
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):387-94. PubMed ID: 27349765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
    Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Hajek R; Pour L; Ozcan M; Martin Sánchez J; García Sanz R; Anagnostopoulos A; Oriol A; Cascavilla N; Terjung A; Lee Y; Briso EM; Dobkowska E; Hauns B; Špička I
    Eur J Haematol; 2020 May; 104(5):435-442. PubMed ID: 31883396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
    Siegel DS; Dimopoulos M; Jagannath S; Goldschmidt H; Durrant S; Kaufman JL; Leleu X; Nagler A; Offner F; Graef T; Eid JE; Houp J; Gause C; Vuocolo S; Anderson KC
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):329-334.e1. PubMed ID: 27025160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
    Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
    Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM
    Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
    Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
    Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.